Guggenheim Maintains Buy on Rapport Therapeutics, Raises Price Target to $70
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Delma Caiati maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $65 to $70.
Guggenheim analyst Delma Caiati maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $65 to $70.